[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Hospital of Orange County\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":228},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,66,91,122,156,184,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100626436","acupuncture-therapy-for-pediatric-disorders-of-gut-brain-interaction-100626436",false,"NCT07435610","Acupuncture Therapy for Pediatric Disorders of Gut-Brain Interaction","A Randomized, Participant- and Assessor-Blinded, Sham-Controlled Trial Investigating Acupuncture for Disorders of Gut-Brain Interaction in Children (P-GAP)","Inclusion Criteria:\n\n1. Age 8-17 years\n2. Diagnosis of FAP-NOS, IBS, or abdominal migraine (Rome IV criteria; partial criteria permitted)\n3. Stable use (≥8 weeks) of antidepressant and\u002For ADHD medications, if applicable\n4. Functional constipation, if present, controlled on maintenance therapy\n5. Ability of participant and caregiver to comply with study procedures\n\nExclusion Criteria:\n\n1. Prior treatment with IB-Stim, acupuncture, or other auricular\u002Fpercutaneous nerve field stimulation modalities.\n2. Diagnosis of functional dyspepsia.\n3. Untreated constipation at screening.\n4. Use of ketamine, opioids, antibiotics, or probiotics within 2 weeks prior to treatment initiation","ALL","8 Years","17 Years",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24],"NA","Disorders of Gut-Brain Interactions (DGBIs) significantly impact children globally, leading to reduced quality of life and increased healthcare utilization. Despite their prevalence, effective treatments for pediatric DGBIs remain limited. Acupuncture, though commonly used in clinical practice and supported by adult data, lacks robust empirical evidence in pediatric populations. This study addresses this critical gap.\n\nThe primary objective is to assess the efficacy of acupuncture in reducing symptom severity in pediatric patients with DGBIs. Key secondary objectives include evaluating improvements in quality of life, functional disability, and mental health outcomes.\n\nThis is a parallel-group, randomized, placebo sham-controlled, participant-blind clinical trial. The study is being conducted in an outpatient pediatric referral center. A total of 96 participants, aged 8-17 years, meeting eligibility criteria for DGBIs will be enrolled. Participants must be medically stable and meet protocol-defined inclusion\u002Fexclusion criteria.\n\nParticipants will be randomly assigned to receive either acupuncture or sham acupuncture, alongside standard care. Treatments will occur over a predefined protocol period. Data will be collected at baseline, during treatment, and at specified post-treatment intervals. The primary outcomes will evaluate changes in pain intensity and frequency. Secondary outcomes will include assessments of pain resolution, quality of life, functional disability, and mental health. Statistical analyses will employ rigorous methodologies to ensure reliability and validity of findings.",[27],"Disorders of Gut-brain Interaction","RECRUITING","2026-06-03",{"date":31,"type":32},"2026-06-05","ACTUAL",{"date":34,"type":32},"2026-01-08",{"date":36,"type":21},"2028-01",{"name":38,"class":39},"Children's Hospital of Orange County","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100384727","phase-2-treatment-of-refractory-infantile-spasms-with-fenfluramine-100384727","NCT04289467","Treatment of Refractory Infantile Spasms With Fenfluramine","A Phase II Study of Fenfluramine for Treatment of Refractory Infantile Spasms","Inclusion Criteria:\n\n* Children ages 12 to 36 months, inclusive\n* Clinical diagnosis of infantile spasms\n* Continued epileptic spasms despite adequate treatment with ACTH and vigabatrin.\n\nExclusion Criteria:\n\n* Significant preexisting cardiovascular disease\n* Exposure to any cannabinoid product within 14 days of screening\n* Initiation or dose-titration of any second-line treatment for infantile spasms in the 14 days prior to screening.\n* Implantation of a vagal nerve simulator within 14 days of screening\n* Initiation and maintenance of the ketogenic diet within 3 months of screening","12 Months","36 Months",{"count":51,"type":21},10,[53],"PHASE2","This is a phase II clinical trial in which children with refractory infantile spasms (also called epileptic spasms or West syndrome) will be treated with fenfluramine, to evaluate efficacy, safety, and tolerability. Patients with infantile spasms that have not responded to treatment with vigabatrin and ACTH we will be invited to participate. Study participants will undergo baseline video-EEG, receive treatment with fenfluramine for 21 days, and then undergo repeat video-EEG to determine effectiveness. Patients with favorable response will have the opportunity to continue treatment for up to 6 months.",[56],"Infantile Spasm","2026-04-13",{"date":59,"type":32},"2026-04-15",{"date":61,"type":32},"2023-06-16",{"date":63,"type":21},"2026-12-31",{"name":38,"class":39},2,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":40},"100437614","percutaneous-electrical-nerve-field-stimulation-penfs-in-patients-with-post-concussion-syndrome-pcs-100437614","NCT04978571","Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)","A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)","Concussion:\n\nInclusion Criteria:\n\n* Clinical diagnosis of Post-Concussion Syndrome\n* Post-Concussion Symptoms for at least 3 months along with lack of other explanation for their symptoms\n* English and Spanish-speaking families\n\nExclusion Criteria:\n\n* Seizure disorders\n* Significant developmental delay\n* Infection or severe dermatological condition of ear\n* Bleeding disorders\n* Implanted electrical device\n\nCOVID:\n\nInclusion Criteria\n\n* Child is in between the ages 11-18\n* Child is present at CHOC Neurology clinic post covid-19 symptoms of more than 3 months duration along with lack of other explanation for their symptoms\n* English-speaking and Spanish-speaking families\n\nYou cannot participate in this study if you meet the following exclusion criteria:\n\n* Children with significant developmental delay, infection or severe dermatological condition of ear, bleeding disorders, or having any implanted electrical device will be excluded.\n* Are not able to attend Friday appointments for the Neurostim placements.","11 Years","18 Years",{"count":76,"type":21},125,[24],"The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms.\n\nAn additional purpose of this study is to demonstrate that PENFS improves functioning in children with post Covid-19 symptoms.",[80,81,82],"Post-Concussion Syndrome","COVID Long-Haul","COVID-19","2026-03-16",{"date":85,"type":32},"2026-03-18",{"date":87,"type":32},"2021-02-01",{"date":89,"type":21},"2027-01",{"name":38,"class":39},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":74,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":103,"conditions":104,"keywords":110,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":121,"locationsCount":4},"100624789","phase-4-the-role-of-ferric-carboxymaltose-in-the-treatment-of-pediatric-iron-deficiency-anemia-in-the-emergency-department-100624789","NCT07414199","The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department","ED-Heme FCM","Inclusion Criteria:\n\n* 1 year to 18 years of age\n* Lab results indicative of anemia due to iron deficiency with Hb between 6.0 g\u002FdL-10.0 g\u002FdL for age and gender\n* Patient is hemodynamically stable\n\nExclusion Criteria:\n\n* Patients \\\u003C1 year or \\> 18 years of age\n* Patients with normal Hb or Hb \\\u003C6 g\u002FdL\n* Overt Bleeding (excluding menstrual bleeding)\n* Traumatic etiology for blood loss\n* Malignancy\n* Thrombocytopenia (platelets \\\u003C100k)\n* Active infection","1 Year",{"count":100,"type":21},150,[102],"PHASE4","The goal of this project is to assess the feasibility, clinical effectiveness, and cost-effectiveness of IV iron therapy using ferric carboxymaltose (FCM) as a treatment for pediatric patients with iron deficiency anemia (IDA) in the emergency department (ED).\n\nThe primary objectives are to:\n\n1. examine and compare healthcare utilization and clinical outcomes of IV FCM use in the pediatric ED compared to historical cohort.\n2. determine the feasibility of IV FCM in the pediatric ED.\n\nA secondary objective of this study is to evaluate if additional laboratory markers such as soluble transferrin receptor (sTfR) or reticulocyte hemoglobin equivalent can serve as potential surrogate markers for diagnosing and monitoring treatment response of IDA between oral iron and IV FCM.\n\nBy evaluating clinical outcomes such as the time to resolution of anemia, hospitalization rates and need for PRBC transfusion, assessing the feasibility of FCM implementation, and secondarily exploring potential adjunct markers for monitoring IDA, this study aims to fill the current research gap and potentially revolutionize management of IDA in pediatric emergency care.",[105,106,107,108,109],"Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease","Iron Deficiency Anaemia Due to Dietary Causes","Iron Deficiency Anemia Treatment","Iron Deficiency Anemia Secondary to IBD or Gastric Bypass","Iron Deficiency Anemias",[111,112,113],"Iron deficiency","anemia","ferric carboxymaltose","NOT_YET_RECRUITING","2026-02-10",{"date":117,"type":32},"2026-02-17",{"date":119,"type":21},"2026-01-31",{"date":63,"type":21},{"name":38,"class":39},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":129,"sex":16,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":141,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},"100620739","cardiac-structure-and-function-in-mps-100620739","NCT07361536","Cardiac Structure and Function in MPS","Cardiovascular Structure and Function in Mucopolysaccharidosis Types I and IVA","Inclusion Criteria:\n\n1. Any Participant with a molecularly confirmed diagnosis of mucopolysaccharidosis is eligible to enroll in this study\n2. Any healthy participant without a diagnosis of mucopolysaccharidosis whose age and biological sex can be matched with an enrolled mucopolysaccharidosis participant\n3. Parental \u002F patient informed consent\n\nExclusion Criteria:\n\n1. Any reason that the investigators would deem a patient not eligible to participate in this study\n2. Inability to participate in the assessments required for this study",true,"0 Years","99 Years",{"count":133,"type":21},240,"OBSERVATIONAL","The purpose of this study is to better understand how heart and blood vessel problems develop in people with Mucopolysaccharidosis (MPS). The investigators are looking at certain substances in the body called GAGs and proteoglycans to see how they affect the heart. The investigators also want to find reliable blood and urine markers that can help us track heart health and guide future treatments.\n\nThis study aims to answer two main questions:\n\n1. Do people with MPS show faster changes in their blood vessels over time (such as thickening or stiffening of the carotid artery) compared to people without MPS?\n2. Do people with MPS have higher levels of certain proteins in their blood (such as clusterin and inflammatory markers) that are linked to blood vessel changes?\n\nWhat participants will do?\n\nParticipants will complete the following tests once a year for 4 years:\n\n* Carotid ultrasound: an imaging test that looks at the blood vessels in the neck.\n* Echocardiogram: an ultrasound of the heart.\n* Blood draw\n* Urine collection\n\nThese tests help the investigators track changes in heart and blood vessel health over time.",[137,138,139,140],"MPS I","MPS IV A","MPS - Mucopolysaccharidosis","MPS IVA",[142,143,144,145,146],"mucopolysaccharidosis","carotid","cardiovascular","biomarker","observational","2026-01-23",{"date":149,"type":32},"2026-01-26",{"date":151,"type":32},"2025-09-01",{"date":153,"type":21},"2030-04-30",{"name":38,"class":39},3,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":164,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":155},"100582666","phase-2-suramin-for-the-treatment-of-autism-trial-kz101-in-a-male-pediatric-population-with-autism-spectrum-disorder-asd-100582666","NCT06866275","Suramin for the Treatment of Autism Trial: KZ101 in a Male Pediatric Population With Autism Spectrum Disorder (ASD)","Suramin for the Treatment of Autism Trial (STAT): A Randomized, Double Blind, Crossover Trial of KZ101 in a Male Pediatric Population With Autism Spectrum Disorder","STAT-2A","Inclusion Criteria:\n\n\\- Subject must meet all of the following criteria to be enrolled in this study.\n\n1. Male, aged 5-14 years\n2. Clinical diagnosis of ASD by DSM-5 criteria\n3. ADOS-2 ≥ 7 on the comparison score for Modules 2-4 (completed within the last 2 years).\n4. CGI-S ≥ 4 for socialization specific symptoms of ASD\n5. Leiter-3 non-verbal IQ \\> 70\n6. Standard score \\\u003C 75 on the Socialization Domain of the Comprehensive Interview Form of the Vineland Adaptive Behavior Scale Third Edition\n7. Subjects who are sexually active or potentially sexually active agree to use condoms with a spermicidal as a barrier method of contraception during the treatment period and for at least 30 days after the last dose of study medication\n8. Subjects agree to wear sunscreen and to wear skin covering to the maximal degree tolerated by the child for the duration of the treatment period and for at least 30 days after the last dose of study medication\n9. Subjects must have a ≤ 90 minutes car ride from the study site\n10. English-speaking child and parent\u002Fguardian or caregiver\n11. Parent or their legal guardians must be willing to sign informed consent\n\nExclusion Criteria:\n\n* Subjects who meet any of the following criteria will be excluded from the study.\n\n  1. ASD diagnosis with underlying syndromic diagnosis (e.g., Fragile X, Angelman, Down's Syndrome, etc.)\n  2. ≤ 5th percentile for weight\n  3. Unable to tolerate venipuncture or urine collection\n  4. Acute infection (e.g., upper respiratory tract infection, common cold, flu, strep, COVID-19)\n  5. Severe co-morbid conditions (e.g., psychosis, seizures\u002Fepilepsy uncontrolled by medication, presence of severe visual or hearing impairment) that may interact with study procedures. Controlled epilepsy is allowed providing there has not been a breakthrough seizure in the past year.\n  6. Any organ system dysfunction, especially liver (e.g., ALT or AST ≥ 1.5x the upper limit of normal), kidney (estimated glomerular filtration rate or eGFR \\\u003C 90 mL\u002Fmin\u002F1.73 m2; hematuria confirmed by urine microscopy \\[ \\> 5 red blood cells\u002Fhigh power field\\]; proteinuria \\[\\> 1+ that does not resolve on repeat testing or urine protein to creatinine ratio \\> 0.3\\]; and\u002For presence of any granular, mixed cellular, red blood cell, white blood cell, or muddy brown casts on urine microscopy), or clinically relevant heart or adrenal abnormalities\n  7. Hospitalization within the previous 2 months from screening\n  8. Initiation or change in pharmacotherapy within previous 2 months from screening\n  9. Initiation or change in psychosocial interventions (formal behavioral, cognitive, or cognitive-behavior therapy) within previous 2 months from screening\n  10. Plan to initiate or change pharmacotherapy or psychosocial interventions during the study\n  11. Taking prescription medication that may interact adversely with KZ101 or expose the subject to increased risk of harm such as medications with plasma bound substances including sulfonamides, chlorpromazine, and anti-coagulants\n  12. Currently enrolled in another clinical study or has received any investigational treatment within 30 days of screening\n  13. Taking \\> 3 medications addressing behavioral symptoms related to ASD (ie typical\u002Fatypical antipsychotics and alpha-adrenergic agonists) or comorbid medical conditions such as ADHD, anxiety, or depression. Anti-seizure medications and other medications not related to neurobehavioral symptoms do not count towards the total number of medications allowed.\n  14. History of serious dermatological reactions\n  15. History of allergy, intolerance, or photosensitivity to any drug\n  16. Unable or unwilling to adhere to study requirements","MALE","5 Years","14 Years",{"count":168,"type":21},45,[53],"Suramin has been found to correct the symptoms, metabolism, and brain synaptic abnormalities in two classical genetic and environmental mouse models of autism. A preliminary clinical trial (SAT-1) examined the safety and activity of a single low-dose of suramin in children with ASD and concluded suramin showed promise as a novel approach to treatment of ASD. The current study, STAT-2A, will be a randomized, double-blind, crossover, 30-week study to evaluate the preliminary proof of concept, safety, and PK of suramin sodium (KZ101) with repeat dosing by IV infusion in males 5-14 years of age who have been diagnosed with ASD. The study will be conducted at approximately 3 sites contributing approximately 15 subjects per site. Total enrollment of approximately 45 subjects is planned to achieve approximately 36 participants completing the study.",[172],"Autism Spectrum Disorder (ASD)",[174,175],"Suramin","suramin sodium","2026-01-05",{"date":178,"type":32},"2026-01-07",{"date":180,"type":32},"2025-04-09",{"date":182,"type":21},"2028-04",{"name":38,"class":39},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":190,"maxAge":74,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":40},"100575467","one-up-one-down-analyzing-patient-preference-on-cryotherapy-machine-tubing-placement-100575467","NCT06772662","One Up, One Down: Analyzing Patient Preference on Cryotherapy Machine Tubing Placement","Inclusion Criteria:\n\n* Patients scheduled for an arthroscopic ACL reconstruction (CPT 29888) or MPFL reconstruction\u002Faugmentation with internal brace (CPT 27422 or 27429)\n* Ages 10-18 years old at the time of surgery\n* Patients who have access to a cryotherapy unit at the time of surgery\n\nExclusion Criteria:\n\n* No ACL reconstruction (CPT 29888) nor MPFL reconstruction\u002Faugmentation with internal brace (CPT 27422 or 27429) performed during knee arthroscopy (i.e., isolated meniscus repair, synovectomy\u002Fdebridement, etc.)\n* Patients do not have access to a cryotherapy unit\n* Patients less than 10 or older than 18 at the time of surgery","10 Years",{"count":192,"type":21},100,[24],"The purpose of this research study is to better understand patient preference and their satisfaction rates with cryotherapy machines based on the direction of the tubing. This study will evaluate both satisfaction and pain of patients who use the cryotherapy machines in the two groups: tubing facing towards the head, and the other with tubing facing toward the feet.",[196],"Cryotherapy Tubing Placement","2025-03-11",{"date":199,"type":32},"2025-03-13",{"date":201,"type":32},"2025-01-08",{"date":203,"type":21},"2026-01-01",{"name":38,"class":39},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":65},"100477817","early-phase-1-use-of-levocarnitine-to-reduce-asparaginase-hepatotoxicity-in-patients-with-acute-lymphoblastic-leukemia-100477817","NCT05501899","Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Patients aged 5 to \\\u003C 30 years\n* Newly diagnosed with ALL designated as NCI high-risk (HR) ALL\n* Treatment for ALL to be according to a Children's Oncology Group (COG) treatment protocol (on study or according to study)\n* Ability to take oral medications and willing to adhere to the levocarnitine regimen\n\nExclusion Criteria:\n\n* Known allergic reaction to levocarnitine or its components\n* Presence of severely compromised renal function or end-stage renal disease\n* Pregnancy or lactation\n* Warfarin therapy\n* History of seizures prior to ALL diagnosis\n* Known inborn error of metabolism","29 Years",{"count":213,"type":21},20,[215],"EARLY_PHASE1","Acute lymphoblastic leukemia (ALL) is the most common cancer seen in pediatric oncology. The necessary chemotherapy for pediatric and adolescent and young adult (AYA) patients with ALL includes steroids, anthracyclines, asparaginase, and vincristine. One of the most hepatotoxic chemotherapy agents is asparaginase, with treatment-associated hepatotoxicity (TAH) observed in up to 60% of patients. The frequency of TAH is increased in overweight or obese patients of Latino heritage. Carnitine is a naturally-derived compound that is produced in the liver and kidneys; it is found in certain foods, such as meat, poultry, fish, and some dairy products. Endogenous carnitine transports long-chain fatty acids into the mitochondria, where they are oxidized to produce energy, and acts as scavengers of oxygen free radicals. Thus, carnitine can reduce oxidative stress and modulate inflammatory response. Levocarnitine is a supplement form of carnitine used typically in the care and management of patients with carnitine deficiency. Pediatric and AYAs with ALL will be given oral levocarnitine as a supplement during their initial phases of treatment, when the most hepatotoxic agents are administered, to determine if the incidence of liver toxicity can be reduced or eliminated.",[218,219],"Acute Lymphoblastic Leukemia","Hepatotoxicity","2024-08-20",{"date":222,"type":32},"2024-08-21",{"date":224,"type":32},"2023-03-03",{"date":226,"type":21},"2024-12-31",{"name":38,"class":39},""]